In a groundbreaking step that could revolutionize emergency medicine, Japanese researchers have launched clinical trials of artificial blood that works for all blood types. Led by Professor Hiromi Sakai at Nara Medical University, the research could bring a life-saving solution to blood shortages and compatibility issues in healthcare systems worldwide.
The artificial blood—created using hemoglobin extracted from expired donor blood—is encased in a protective shell that makes it stable and virus-free. Unlike regular donated blood, which expires after 42 days and must be matched to blood types, this universal artificial blood is shelf-stable for up to two years and requires no compatibility testing.
Sixteen healthy adult volunteers received 100 to 400 milliliters of this synthetic blood in March. If proven safe and effective, Japan could become the first country to use artificial blood in real-world treatments by 2030.
“The need for artificial blood cells is significant as there is currently no safe substitute for red cells,” said Prof. Sakai.
Social media has reacted with awe and optimism. Many users called the project “Nobel Prize-worthy,” while others praised Japan’s leadership in medical innovation—highlighting recent efforts such as tooth regrowth and anti-aging treatments for pets.
Meanwhile, in the US, researchers have also been working on a similar product called ErythroMer, which uses recycled hemoglobin and has already entered pre-clinical testing. Backed by a $46 million DARPA grant, this version is being developed to be shelf-stable and deployable in field conditions.
If successful, these advances could dramatically change how hospitals and disaster zones manage blood supplies—saving countless lives in situations where speed, availability, and compatibility matter most.